Chemical | 08 February 2021
Jubilant Pharmova Q3FY21 consolidated PAT at Rs. 309.93 Cr
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
Linde's sales for the fourth quarter were $7,272 million, 3% above prior year and 6% sequentially.
The company has also been confronted with rising costs for packaging, transportation and environmental obligations.
The company posted net profit of Rs.1.24 crores for the period ended December 31, 2019.
The company has posted net profit of Rs.24.89 crores for the 9 months period ended December 31, 2020.
The company posted net profit of Rs.0.67 crores for the period ended December 31, 2019.
Orobanche a serious hidden parasitic weed in mustard cause severe yield loss to the extent of up to 50%.
The company posted net profit of Rs.0.90 crores for the period ended December 31, 2019.
The company has posted net profit of Rs.72.11 crores for the 9 months period ended December 31, 2020.
The company posted net profit of Rs.31.47 crores for the quarter ended December 31, 2019.
The company posted net profit of Rs.6.63 crores for the period ended December 31, 2019.
The company posted net profit of Rs.2.28 crores for the period ended December 31, 2019.
The company posted net profit of Rs.78.42 crores for the period ended December 31, 2019.
The company posted net profit of Rs.2.16 crores for the period ended December 31, 2019.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
The plants are due to be completed in 2024
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Subscribe To Our Newsletter & Stay Updated
_280_300.jpg)
